Alisporivir

Drug Profile

Alisporivir

Alternative Names: DEB-025; DEBIO-025; DEBIO-25

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Debiopharm
  • Developer Debiopharm; Solid Biosciences
  • Class Ciclosporins
  • Mechanism of Action Cyclophilin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Hepatitis C
  • Preclinical Duchenne muscular dystrophy

Most Recent Events

  • 01 Apr 2016 Novartis terminates phase III trial in Hepatitis C (combination therapy, treatment-naive African American patients) in USA (NCT01446250)
  • 08 Sep 2015 Debiopharm International and Solid Biosciences collaborated to co-develop alisporivir for Duchenne muscular dystrophy
  • 08 Sep 2015 Preclinical trials in Duchenne muscular dystrophy in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top